Product image of Mirabegron Teva (Mirabegron) supplied by GNH India

Mirabegron Teva

Active Ingredient:
Mirabegron
Origin:
EU

Mirabegron Teva (Mirabegron)

Mirabegron, the active ingredient in Mirabegron Teva, is a beta‑3 adrenergic receptor agonist presented as an oral tablet for oral use. It is indicated for the treatment of overactive bladder symptoms such as urinary urgency, frequency and urge incontinence in adults.

GNH India supplies Mirabegron Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Our distribution network ensures timely delivery and compliance with local regulatory requirements.

Manufacturer / TM Owner

Teva Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mirabegron is used to manage conditions related to overactive bladder and urinary urgency.

  • Overactive bladder: reduces urinary urgency, frequency and urge incontinence.
  • Urinary urgency: lessens the sudden need to void.
  • Urinary frequency: decreases the number of daytime voids.
  • Urge urinary incontinence: helps control accidental leakage.

How It Works

  • Mirabegron selectively activates β3‑adrenergic receptors located in the detrusor smooth muscle of the urinary bladder. Stimulation of these receptors increases cyclic AMP levels, leading to relaxation of the detrusor during the storage phase of the micturition cycle. This relaxation expands functional bladder capacity and diminishes involuntary contractions, thereby alleviating symptoms of urgency and frequency associated with overactive bladder.

Side Effects

Adverse reactions reported with Mirabegron vary in frequency and severity.

Common Side Effects

  • Dry mouth: sensation of reduced salivation.
  • Headache: mild to moderate pain in the head.
  • Hypertension: increase in blood pressure.
  • Nasopharyngitis: inflammation of the nasal passages and throat.
  • Constipation: difficulty passing stools.
  • Dizziness: feeling light‑headed or unsteady.

Serious or Rare Side Effects

  • Severe hypertension: markedly elevated blood pressure requiring medical attention.
  • Urinary retention: difficulty emptying the bladder.
  • Tachycardia: abnormally fast heart rate.
  • Angioedema: swelling of the face, lips or airway.
  • Hepatotoxicity: liver enzyme elevations or injury.

Precautions & Warnings

Before prescribing Mirabegron, clinicians should consider several precautionary measures to ensure patient safety.

  • Blood pressure monitoring: check baseline and periodically during therapy.
  • Cardiovascular assessment: evaluate history of arrhythmias or heart disease.
  • Renal function: adjust use in patients with severe renal impairment.
  • Concomitant antihypertensives: monitor for additive blood pressure effects.
  • Pregnancy and lactation: use only if potential benefit justifies risk.
  • Store below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Mirabegron can affect the plasma concentrations of several co‑administered medicines through metabolic pathways.

Major Interactions (Avoid)

  • Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase Mirabegron exposure.
  • Antihypertensive agents (e.g., beta‑blockers, ACE inhibitors): risk of reduced blood pressure control.

Moderate Interactions (Monitor Closely)

  • CYP3A4 substrates (e.g., midazolam, calcium channel blockers): possible altered levels.
  • Diuretics: additive effect on blood pressure.
  • Anticholinergic drugs: may diminish therapeutic benefit for bladder symptoms.

Frequently Asked Questions

Mirabegron Teva is prescribed to treat symptoms of overactive bladder, including urinary urgency, increased frequency of urination, and urge incontinence. By improving bladder storage capacity, it helps patients achieve better control over urinary habits.

Mirabegron works by selectively activating β3‑adrenergic receptors in the detrusor muscle of the bladder. This activation raises cyclic AMP levels, causing the muscle to relax during the filling phase, which expands bladder capacity and reduces involuntary contractions.

The appropriate dose of Mirabegron is determined by a qualified healthcare professional based on the individual patient's condition, renal function, and concomitant medications. Patients should follow the prescriber's instructions and not adjust the dose on their own.

Safety data for Mirabegron during pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by the prescribing clinician.

To place an order, submit an enquiry on the Mirabegron Teva product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabegron belongs to a different drug class than antimuscarinics; it targets β3‑adrenergic receptors rather than muscarinic receptors. This mechanism often results in a lower incidence of dry mouth and constipation, common side effects of antimuscarinic therapy, while providing comparable efficacy for overactive bladder symptoms.

Mirabegron tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiration date indicated on the label.

Mirabegron is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed, crushed, or divided unless specifically instructed by a healthcare professional.

Serious risks include significant hypertension, urinary retention, tachycardia, and rare cases of angioedema or liver injury. Patients should promptly report symptoms such as a sudden rise in blood pressure, difficulty urinating, rapid heartbeat, or swelling of the face or throat to their physician.

Mirabegron is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is advised for individuals with uncontrolled hypertension, severe renal impairment, or those taking strong CYP2D6 inhibitors, unless a prescriber determines that benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mirabegron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT